The United States is aiming to achieve nationwide adoption of electronic health records (EHRs) but lacks robust empirical evidence to anticipate the effect on health care costs.
T
he United States is undertaking a large-scale effort to increase the use of electronic health records (EHRs). The centerpiece of the 2009 Health Information Technology for Economic and Clinical Health (HITECH) Act is $27 billion in incentives to encourage physicians and hospitals to adopt and use EHRs according to federally defined "meaningful use" criteria (1, 2) . The legislation was motivated by the expectation that EHRs would lead to higher-quality, lower-cost care by avoiding inefficiencies, inappropriate care, and medical errors (3) (4) (5) (6) .
The expectation that EHRs will lower health care costs has come under scrutiny. They could do so by several means: Easier access to patient medical records could limit unnecessary office visits by enabling physicians to deal with clinical issues by phone, electronic prescribing could prevent adverse drug events and the associated cost, and access to previous diagnostic test results could decrease duplicative testing. However, many question whether EHR functions, such as test result viewing and computerized order entry, will reduce costs or drive them higher by making information more accessible and easing the ordering processes (7) (8) (9) . Costs could also increase if EHR use reduces rejected claims and helps justify higher reimbursement (10) .
Available empirical evidence has not yet resolved the debate. Evaluations done by a few leading institutions point to health care cost savings (11) (12) (13) (14) . However, the EHRs they evaluated incorporated advanced functionalities optimized for their clinical setting, such as clinical decision support that reduced costs by guiding physicians away from inappropriate tests and procedures (15, 16) . Recent studies, which failed to show savings, focus more narrowly on how EHRs impact the cost of discrete clinical encounters or care delivered by individual physicians or organizations (7) (8) (9) . Although EHR advocates argue that savings will come from "network" effects of EHRs when all practices across the community become wired, we lack supporting evidence.
A Massachusetts experiment enabled us to test the hypothesis that community-wide EHR adoption would result in cost savings. The Massachusetts eHealth Collaborative (MAeHC), launched in 2006, helped 3 communities widely deploy ambulatory EHRs. The experiment, which included subsidized EHR adoption and provision of technical aid, served as a model for the HITECH Act (17) . Because participating providers reported using EHRs in similar ways to the initial meaningful use criteria (for ex-ample, entering medication orders and test result viewing), the MAeHC experiment offers timely data on how the federal meaningful use program may impact costs in the short-term.
We compared health care costs for patients who received most of their care from providers (such as individual clinicians) who adopted EHRs in the experimental pilot communities with those for patients in matched control communities that applied, but were not selected, to be part of the pilot. We evaluated whether the intervention changed the monthly cost trend from the 15 months before implementation to the 18 months after implementation. We examined overall cost and cost in prespecified categories (ambulatory pharmacy, laboratory, and radiology), which evidence suggests are most sensitive to EHR use (11, 12, 14, 16) . All cost measures were derived from claims data and standardized (that is, a dollar weighted value of utilization) to capture a societal perspective.
METHODS

Setting and Intervention
The MAeHC was established to administer a largescale pilot of EHRs in the ambulatory setting (18 -21) . Three communities were selected from 32 in Massachusetts that applied to serve as pilot sites. The MAeHC purposely selected those with heterogeneous populations and a high likelihood of broad adoption to assess the resulting effect on cost and quality. In the 3 communities, 167 practices with a relationship to their community hospital were eligible, 86% of which participated (22) . These practices were largely representative of those in the state (23) . Intervention communities were enthusiastic about participating because of the subsidized EHRs and implementation support, and neither the MAeHC nor the communities pursued specific quality improvement or cost reduction targets.
Each intervention community evaluated and approved up to 4 commercially available EHR systems from which participating practices could choose. The most common systems were from Allscripts (Chicago, Illinois), GE Centricity (Little Chalfont, United Kingdom), eClinicalWorks (Westborough, Massachusetts), and NextGen (Horsham, Pennsylvania) (20) . Although functionality varied by system and practice, most providers used EHRs in ways that were consistent with the priorities of stage 1 meaningful use and were expected to reduce costs: capturing core clinical data electronically, entering medication orders, and viewing tests results (1, 17) ( Table 1) .
System costs and implementation support were almost fully covered by the MAeHC. Implementation began in 
Selection of Control Patients
To maximize comparability of the patient populations assigned to intervention and control communities, we matched communities, matched providers within communities, and selected patients receiving most of their care from matched providers.
To help ensure shared interest in EHR adoption and associated unobserved characteristics, we matched 2 control communities to each intervention community from the pool of applicants. We used several community characteristics to select control communities. We first calculated the standardized difference for each baseline characteristic (that is, the difference between each intervention community and potential control community characteristic, divided by the pooled SD of that characteristic across communities) (24, 25) . Then, we squared and summed standardized differences across all characteristics. The 2 control communities with the smallest total standardized differences relative to an intervention community were chosen. Available survey data (26) confirmed that no control community had widespread EHR adoption at the outset of the analytic period.
Control providers who would have probably participated in the pilot had their community been selected were identified. First, because not all types of providers were
Context
Data are lacking to support speculation that the increase in the use of electronic health records in the United States will result in cost savings by increasing efficiency.
Contribution
This analysis of implementation of EHRs by 806 ambulatory care clinicians in 3 Massachusetts communities did not identify statistically significant cost savings, but the results suggest that EHRs might slow cost increases.
Caution
Pilot communities were not selected at random. Differences between intervention and control communities could contribute to observed findings.
Implication
This pilot study suggests that implementation of EHRs may be associated with modest reduction in growth of health care costs.
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Original Research Short-Term Savings From Ambulatory Electronic Health Records eligible to participate (for example, hospitalists), we used provider specialty data from insurers' directories to identify which specialties had no providers participating in intervention communities and removed them from control communities. Second, because not all eligible providers chose to participate, we estimated a logistic regression model for each intervention community by using observed characteristics that best differentiated their participating providers from nonparticipating providers. We then applied the model to providers in their matched control communities to predict the probability that a given control provider would have been included in the pilot had his or her community been chosen. We selected control providers with the highest probability scores and took the same percentage of providers from control communities as were adopters in the matched intervention community.
Finally, patients were assigned to 1 of the 9 communities if more than half of their ambulatory spending (dollar amount) and ambulatory claims (number of claims, regardless of amount) were billed by intervention or matched control providers in that community (27) .
Outcome Measures
To assess the effect of the intervention on total cost and capture any spillover effects from broad community adoption, we examined all care received by patients assigned to an intervention or a control community, not the subset of care delivered by intervention and matched control providers. This mirrors the early experience under the HITECH Act in which patients receive care from several providers, only some of whom have adopted EHRs.
We created cost measures that reflect a societal perspective by applying a standardized cost from 2009 Medicare fee schedules to each claim based on the diagnosisrelated group or Current Procedural Terminology codes. By using a standardized fee schedule that holds payments for a given service constant across providers and insurers over time, the resulting cost measures capture changes in utilization and not changes in reimbursement rates that could vary by community (28, 29) .
We created a measure of total cost for patients in each month in which they were insured and then split it into inpatient and ambulatory costs. Because the intervention occurred in the ambulatory setting, we further broke down ambulatory cost into pharmacy, laboratory, radiology, and other.
Analytic Models
For each measure, we fitted a longitudinal regression model by using each patient's aggregate monthly cost as the unit of analysis. Time was incorporated by means of a piecewise regression model to account for potential change in trend. We evaluated the effect of the intervention by determining whether the linear trend in the preimplementation period (January 2005 to March 2006) differed from the linear trend in the postimplementation period (January 2008 to June 2009) for patients assigned to intervention communities compared with patients assigned to control communities. The treatment, EHR adoption, is considered cost-saving if the pre-to postimplementation change in cost trend decreases more (absolute reduction) or does not increase as quickly (slower growth in upward trajectory) for intervention patients compared with control patients (Figure 1 of the Supplement, available at www.annals.org).
Because of the skewness of individual medical spending, we assumed that the outcomes followed a gamma distribution and fit a marginal regression model with a log link between the outcome and the predictor variables. This was chosen over a log-normal approach to enhance interpretability of the coefficients and because of its improved efficiency based on the Park residual diagnostics (30) . We accounted for correlation over time and between patients seen by the same provider through the residual terms; moreover, we used a marginal correlation approach implemented via PROC GENMOD in SAS, version 9.3 (SAS Institute, Cary, North Carolina). The marginal model enables a straightforward interpretation of model effects as the effect of EHR implementation across intervention providers (31) and allows for robust SEs by estimating the correlation structure directly from model residuals. We ex- ponentiated model coefficients to interpret results as the monthly percentage change in costs during the pre-and postimplementation periods. Our models also adjusted for seasonal trends and the following patient demographic characteristics, which may change over time in our sample: age, sex, type of coverage (for example, HMO), and Charlson comorbidity index conditions. We decided a priori to estimate each model twice-once for all patients and once limited to the subset of patients with 1 or more chronic diseases because we hypothesized that the intervention effect may differ for a sicker population. Subsequently, we examined results for HMO and non-HMO patients. Although HMO patients' utilization may be better managed overall, limiting the potential opportunity for further reduction from EHR adoption, providers may be more motivated to use newly adopted EHRs to reduce costs if they can collect the resulting savings.
To better understand the magnitude of our effect estimates, we predicted costs from our models at 3 time points: start of the preimplementation period, start of the implementation period, and end of the postimplementation period. We also generated savings projections by calculating the average projected cost per member per month (PMPM) over the 18-month postimplementation period under 2 scenarios: cost changes based on the experience in the intervention communities and cost changes based on the experience in the control communities. The difference between the former and the latter represents the cost effect of the intervention.
Role of the Funding Source
Our funding source, the MAeHC, provided the names of participating providers and applicant communities, but was not otherwise involved in the design, conduct, or analysis of the study and publication decisions.
RESULTS
Sample
Our analytic sample included 4 812 412 patientmonth observations from 47 979 intervention patients and 130 603 control patients who received most of their care from 806 intervention providers or 1597 matched control providers (Tables 2 and 3).
Total Cost
Total cost increased 0.78 absolute percentage point in intervention and 1.09 absolute percentage points in control communities (difference in change in trend, Ϫ0.30 percentage point [95% CI, Ϫ0.70 to 0.09 percentage points]; P ϭ 0.135) ( Table 4) . Associated predicted PMPM costs at the start of the preimplementation period were $151 among intervention patients and $155 among Includes myocardial infarction and congestive heart failure. Table 1 , available at www .annals.org). Fifteen months later, at the start of implementation, these had increased to $158 PMPM for both groups. By the end of the postimplementation period, projected PMPM costs were $173 among intervention patients compared with $179 among control patients. 
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Subtypes of Cost
Whereas inpatient cost did not reflect a statistically significant pre-to postimplementation difference (absolute difference in monthly trend change, 0.18 percentage point [CI, Ϫ2.51 to 2.94 percentage points]; P ϭ 0.90), ambulatory costs increased more slowly in intervention than control communities (absolute difference in monthly trend change, Ϫ0.35 percentage point [CI, Ϫ0.63 to Ϫ0.08 percentage points]; P ϭ 0.012) ( Table 4) . Ambulatory pharmacy, laboratory, and radiology costs all favored intervention patients, but only radiology cost was statistically significant. The estimated absolute difference in monthly trend change was Ϫ0.35 percentage point for pharmacy costs (CI, Ϫ0.84 to 0.14 percentage points; P ϭ 0.167) and Ϫ0.38 percentage point for laboratory costs (CI, Ϫ0.79 to 0.02 percentage points; P ϭ 0.061). Radiology costs exhibited the largest difference of Ϫ1.61 percentage points (CI, Ϫ2.26 to Ϫ0.95 percentage points; P Ͻ 0.001); it was the only outcome with an absolute decrease in monthly cost growth in the pre-to postimplementation periods for intervention patients (from 1.03% to 0.60%), whereas the cost trajectory increased among control patients.
Costs Among Subgroups
The 25% of the population (12 139 intervention patients and 28 813 control patients) with chronic diseases showed no statistically significant pre-to postimplementation difference in total cost (absolute difference in monthly trend change, Ϫ0.14 percentage point [CI, Ϫ0.73 to 0.45 percentage points]; P ϭ 0.66) or for inpatient or ambulatory cost. For ambulatory radiology, monthly cost growth decreased (absolute difference in trend change, Ϫ1.62 percentage points [CI, Ϫ2.58 to Ϫ0.66 percentage points]; P ϭ 0.001) ( Table 5) .
Among HMO patients, who constituted most of the population (n ϭ 102 332 [57%]), we found evidence for savings in total and ambulatory costs (Appendix Table 2 , available at www.annals.org). Pharmacy, laboratory, and radiology costs increased more slowly among HMO patients in the intevention communities than in the control communities. In contrast, among non-HMO patients, the pilot resulted in only ambulatory radiology savings (Appendix Table 3 , available at www.annals.org).
Estimated Cost Effect
Relative to the average PMPM total cost of $151.13 across the 3 intervention communities in the preimplementation period, the $5.14 in projected average PMPM savings over the 18 months after implementation represents 3.40% savings ( Table 6 ). The associated CI around this point estimate is 15.00% ($21.95) to Ϫ1.01% (Ϫ$1.53). Ambulatory cost accounts for most of the savings, with $4.69 in projected PMPM savings (3.10% of total PMPM cost [CI, 5.59% to 0.72%]). Savings in radiology were $1.61 PMPM (1.07% of total PMPM cost [CI, 1.46% to 0.65%]) ( Table 6 ). Assuming $5.14 PMPM savings for the 47 979 intervention patients, it would take approximately 7 years to recoup the projected 5-year adoption cost in the pilot communities of $130 822 per provider (10). PMPM ϭ per member per month. * Statistically significant (P Ͻ 0.05) difference in change in trend. † Derived from the value of assuming a trend in the control community minus the value of assuming a trend in the intervention community. ‡ The denominators are the values in the first row. § The denominator is $151.13.
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DISCUSSION
We used a natural experiment in community practices to address an important gap in the literature on the effect of EHRs on health care costs. Our study offers robust evidence on the likely short-term effect of the federal policy effort to promote meaningful use of EHRs. The setting was typical of practices that deliver ambulatory care in the United States. Practices were mostly small, with a mix of primary and specialty care, and used commercially available EHRs to perform the core clinical tasks that are required of physicians in the first stage of meaningful use. In the 18 months after adoption, we saw ambulatory cost savings of 3% PMPM and reductions in ambulatory radiology cost. If sustained for a sufficiently long period, these could translate to substantial savings.
Pilot providers reported that viewing laboratory and radiology test results were among the most common uses of their EHRs ( Table 1) . Easier access to previous results may have prompted providers to order fewer tests, particularly in radiology. Reducing these ancillary costs may have been facilitated by the fact that most ordering providers would not incur the associated lost revenue. Our failure to find a statistically significant reduction in total cost may be explained by providers not using EHRs in more advanced ways that would improve patient health status, thereby avoiding hospitalizations and other high-cost episodes. The disruption caused by EHR adoption could have made it difficult for providers to learn how to use EHRs to monitor population health, better coordinate care, or engage in more sophisticated use.
Studies examining the effect of ambulatory EHRs on specific types of costs report mixed findings. Recently, a national cross-sectional study found that electronic availability of test results was associated with an increased likelihood of ordering diagnostic tests among physicians (7), but reductions in radiology and clinical laboratory services were seen after EHR adoption in 2 Kaiser Permanente regions, with a 14% decrease in the use of radiology services in 1 region (14) . A small controlled trial also found reductions in radiology and laboratory use when physicians were shown past test results electronically (13) . Our study provides more generalizable evidence for savings in these 2 domains and extends the literature by examining the effect on total cost.
Our study has several limitations. Although we used many strategies to improve comparability (limiting control communities to those that applied to be pilot sites, matching control and intervention communities on a broad range of characteristics, narrowing providers within control communities to those with characteristics similar to intervention providers, adjusting for differences in member demographic characteristics, and examining whether the change in cost trend differed), we may not have controlled for all confounding, including temporal trends that could have differentially affected utilization in specific communities. In addition, pilot communities were not randomly selected. The MAeHC intentionally chose communities that were heterogeneous and had a strong likelihood of successful EHR adoption, suggesting that our results may represent a best-case scenario.
Our data capture costs incurred in the private market and by relatively young patients; therefore, effect sizes may be larger in Medicare or Medicaid populations. Although we determined that control communities had low levels of EHR adoption at the start of the pilot, some could have increased this on their own after they were not selected to participate, which could have led to an underestimate in savings. The substantial resources devoted to implementing EHRs in practices in the intervention communities were not netted out of savings estimates. Because similar resources are unlikely to be available outside the pilot, our findings may overestimate the savings resulting from community-based EHR adoption. Finally, we were not able to evaluate the clinical appropriateness of changes in utilization that we saw.
In summary, we examined a large, ambulatory EHR pilot to assess the effect on short-term health care costs. Adoption of EHRs resulted in ambulatory cost savings, with particularly strong evidence for savings in radiology. Reducing health spending by the magnitude that we observed would result in substantial savings if sustained over several years. Larger savings are possible if providers have incentives to deliver more efficient care. Efforts to reform financing and delivery of care alongside greater use of EHRs may focus clinicians' attention on how best to leverage their EHR to achieve savings and help realize the full benefit from our large national investment in EHRs. 
